RxDoctor Payments Data

Jessica Gray, MD

Family Medicine · Lubbock, TXNPI 1851785000

Payments from drug & device makers

$15,330in general payments, 2019–2025

Across 312 payments — averaging $49.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$10K
  • AbbVie$782
  • Lilly USA, LLC$659
  • Pfizer$628
  • Abbott$468
  • GSK$408
  • plus $2K from 31 others

What the payments were for

  • Speaking & faculty fees$9,91765%
  • Travel & lodging$3182%
  • Food & beverage$4,99533%
  • Education$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,330 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,050
Medicare patients
135
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$58,834
JardianceEmpagliflozin42$48,472
OzempicSemaglutide44$41,464
EliquisApixaban24$25,581
ProliaDenosumab14$23,339
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,045
TrulicityDulaglutide19$19,929
RybelsusSemaglutide12$11,433
FarxigaDapagliflozin Propanediol12$11,412
Emgality PenGalcanezumab-Gnlm11$7,771
Levothyroxine Sodium309$4,148
Atorvastatin Calcium245$2,456
Raloxifene Hcl26$1,562
Rosuvastatin Calcium141$1,489
Albuterol Sulfate HfaAlbuterol Sulfate55$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$659$78,76475 claims
Novo NordiskOzempic, Rybelsus$203$52,89756 claims
Boehringer IngelheimJardiance$18$48,47242 claims
PfizerEliquis$628$25,58124 claims
AmgenProlia$130$23,33914 claims
GSKTrelegy Ellipta$408$22,04532 claims
AstraZenecaFarxiga$202$11,41212 claims
AbbVieSynthroid$782$1,25626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →